undamentalytics Newsletter
Sign in

Invivyd, Inc. revenue

Invivyd, Inc.'s revenue was $53.4m in fiscal 2025, up 110.5% on the year before. Over the last twelve months it was $58.4m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0255358
Growth on the year before——+110.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Invivyd, Inc. $58.4m 26.3% —
Fennec Pharmaceuticals Inc. $59.2m 77.8% 566.5%
Intellia Therapeutics, Inc. $59.5m 12.6% 3.9%
Nektar Therapeutics $54.6m -27.2% -14.6%
Tango Therapeutics, Inc. $53.8m 121.5% 16.9%
Siga Technologies Inc $53.7m -70.1% -18.1%

Compare with peers

Head to head: FENC vs IVVDIVVD vs NTLAIVVD vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Invivyd, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Invivyd, Inc.